_{The high production capacity allows producing approximately 12 billion therapeutic doses per year}

Prati-Donaduzzi, Brazil's largest manufacturer of doses of generic drugs, celebrates 25 years of history on December 3rd. Located in Toledo, western Paraná, the company had its beginning encouraged by programs of the State Government and the City of Toledo, in a shed with few equipment and employees. 

Nowadays, there are more than 4.3 thousand jobs in a wide structure equipped with the most modern for the production of medicines. In an integrated business system, the industry has lines of research and development of medicines, production of packaging up to the transport of the product destined to the final consumer. 

The expressive presence of Prati-Donaduzzi allows medicines to reach all Brazilian states. "Each dose we produce leads to those who need our Mission to provide health and well-being to people, allowing access to treatment with quality and effectiveness. This is only possible because we rely on the dedication and commitment of our employees every day", emphasizes Prati-Donaduzzi CEO, Eder Fernando Maffissoni. 

The high production capacity allows producing approximately 12 billion therapeutic doses per year, which represents a potential treatment for about 25 million people daily. These results have enabled the industry to gain prominence and become the largest supplier of generic medicines to the Government, which is present in more than 90% of the 5,510 cities with Basic Health Units (UBS) in Brazil.

"From the beginning, the history of Prati-Donaduzzi was based on ethics and seriousness, factors that coupled with the founders' entrepreneurial vision, are the foundations that allow the rapid and sustainable growth of the company in recent years", adds Maffissoni.

In the area of ​​social responsibility, the company develops eight projects that serve both the internal public and the community. These are initiatives focused on training and professional development, as well as care for the environment.

New Business

With an investment of around 5% of net revenue in innovation, Prati-Donaduzzi works on projects that allow the opening of new markets. Among the initiatives, the development of a portfolio focused on prescription drugs is highlighted.

As an example of these investments, Prati-Donaduzzi expects to register for the first half of 2019 the product Myalo® - a drug based on Cannabidiol (CBD) and indicated for the control of refractory epilepsy crises, the most critical stage of the disease, whose incidence is more common in children. The research started in 2015 is now in the clinical trials phase in patients and happens in partnership with Faculty of Medicine of the University of São Paulo - USP / Ribeirão Preto.

Another project that stands out as a pioneer in the world contemplates the development of synthetic-based Cannabis, which will be produced from structurally simpler and commercially available chemical substances, meeting the quality requirements required for an active pharmaceutical input (IFA) both in the Brazil (Anvisa) and abroad (ICH).

Last year the company entered the functional food market with the launch of Sensilatte - an enzyme for people who have lactose intolerance. In addition, in search of new opportunities, Prati-Donaduzzi won in 2018 the certification that allows exporting dietary supplements to the United States. Authorization was granted through an audit conducted by the National Sanitation Foundation (NSF) and the first batches came out in November from the industry. Currently, the company has a line with 11 dietary supplements in commercialization in Brazil, such as multivitamins, omega 3, coconut oil, among others.

"These opportunities and investments take us to a new level and are important milestones in our history. Seeing the quality of our products being recognized in first world countries is a source of pride", adds the CEO.

2019

For the next year, Prati-Donaduzzi aims to grow its revenues by 15% compared to 2018, and to double it in the next five years. One of the actions planned for 2019 is the expansion of the product portfolio with the forecast of launching approximately 40 new molecules, most of them in the central nervous system.  

 _{*IQVIA MAT SEPTEMBER/2018 PMB + NRC THERAPEUTIC DOSES}